These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32280516)

  • 1. Systemic Factors Associated with Treatment Response in Diabetic Macular Edema.
    Wong WM; Chee C; Bhargava M; Chai C; Lin H; Zhao P; Ariadarma Mangunkusumo E; Naing T; Yuen YS; Wong TY; Su X; Lingam G
    J Ophthalmol; 2020; 2020():1875860. PubMed ID: 32280516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aqueous Humor Cytokine Levels and Anatomic Response to Intravitreal Ranibizumab in Diabetic Macular Edema.
    Hillier RJ; Ojaimi E; Wong DT; Mak MYK; Berger AR; Kohly RP; Kertes PJ; Forooghian F; Boyd SR; Eng K; Altomare F; Giavedoni LR; Nisenbaum R; Muni RH
    JAMA Ophthalmol; 2018 Apr; 136(4):382-388. PubMed ID: 29522144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retinal Layers Changes in Patients with Diabetic Macular Edema Treated with Intravitreal Anti-VEGF Agents: Long-Term Outcomes of a Spectral-Domain OCT Study.
    Chatziralli I; Kazantzis D; Theodossiadis G; Theodossiadis P; Sergentanis TN
    Ophthalmic Res; 2021; 64(2):230-236. PubMed ID: 32564022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment clinical variables associated with the response to intravitreal bevacizumab (Avastin) injection in patients with persistent diabetic macular edema.
    Warid Al-Laftah FA; Elshafie M; Alhashimi M; Pai A; Farouq M
    Saudi J Ophthalmol; 2010 Oct; 24(4):133-8. PubMed ID: 23960890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of metabolic parameters on clinical response to VEGF inhibitors for diabetic macular edema.
    Matsuda S; Tam T; Singh RP; Kaiser PK; Petkovsek D; Carneiro G; Zanella MT; Ehlers JP
    J Diabetes Complications; 2014; 28(2):166-70. PubMed ID: 24374138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of Response between Both Eyes to First- and Second-Line Anti-VEGF Therapy in Diabetic Macular Edema.
    Tiosano L; Ayalon A; Banin E; Averbukh E; Jaouni T; Chowers I
    Curr Eye Res; 2021 Apr; 46(4):539-545. PubMed ID: 32804540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dril Influences Short-term Visual Outcome after Intravitreal Corticosteroid Injection for Refractory Diabetic Macular Edema.
    Luís ME; Sampaio F; Costa J; Cabral D; Teixeira C; Ferreira JT
    Curr Eye Res; 2021 Sep; 46(9):1378-1386. PubMed ID: 33463388
    [No Abstract]   [Full Text] [Related]  

  • 8. Association of Circulating Markers With Outcome Parameters in the Bevacizumab and Ranibizumab in Diabetic Macular Edema Trial.
    Fickweiler W; Klaassen I; Vogels IM; Hooymans JM; Wolffenbuttel BH; Los LI; Schlingemann RO;
    Invest Ophthalmol Vis Sci; 2016 Nov; 57(14):6234-6241. PubMed ID: 27842163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetic macular edema treated with ranibizumab following bevacizumab failure in Israel (DERBI study).
    Ehrlich R; Pokroy R; Segal O; Goldstein M; Pollack A; Hanhart J; Barak Y; Kehat R; Shulman S; Vidne O; Abu Ahmad W; Chowers I
    Eur J Ophthalmol; 2019 Mar; 29(2):229-233. PubMed ID: 29916263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of visual acuity based on optical coherence tomography patterns following intravitreal bevacizumab treatment in patients with diabetic macular edema.
    Cheema HR; Al Habash A; Al-Askar E
    Int J Ophthalmol; 2014; 7(2):251-5. PubMed ID: 24790866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ranibizumab versus aflibercept for diabetic macular edema: 18-month results of a comparative, prospective, randomized study and multivariate analysis of visual outcome predictors.
    Chatzirallis A; Theodossiadis P; Droutsas K; Koutsandrea C; Ladas I; Moschos MM
    Cutan Ocul Toxicol; 2020 Dec; 39(4):317-322. PubMed ID: 32722955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab.
    Bressler SB; Qin H; Beck RW; Chalam KV; Kim JE; Melia M; Wells JA;
    Arch Ophthalmol; 2012 Sep; 130(9):1153-61. PubMed ID: 22965591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4.
    Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; King J; Antoszyk AN; Peters MA; Tolentino M;
    JAMA Ophthalmol; 2017 Jun; 135(6):639-649. PubMed ID: 28492860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema.
    Nepomuceno AB; Takaki E; Paes de Almeida FP; Peroni R; Cardillo JA; Siqueira RC; Scott IU; Messias A; Jorge R
    Am J Ophthalmol; 2013 Sep; 156(3):502-510.e2. PubMed ID: 23795985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of intravitreal anti-VEGF on choroidal thickness in patients with diabetic macular edema using spectral domain OCT.
    Kniggendorf VF; Novais EA; Kniggendorf SL; Xavier C; Cole ED; Regatieri CV
    Arq Bras Oftalmol; 2016; 79(3):155-8. PubMed ID: 27463625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of intravitreal anti-vascular endothelial growth factor or steroid injection in diabetic macular edema according to fluid turbidity in optical coherence tomography.
    Lee K; Chung H; Park Y; Sohn J
    Korean J Ophthalmol; 2014 Aug; 28(4):298-305. PubMed ID: 25120338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atrophy of the central neuroretina in patients treated for diabetic macular edema.
    Karst SG; Schuster M; Mitsch C; Meyer EL; Kundi M; Scholda C; Schmidt-Erfurth UM
    Acta Ophthalmol; 2019 Dec; 97(8):e1054-e1061. PubMed ID: 31228332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
    Virgili G; Parravano M; Evans JR; Gordon I; Lucenteforte E
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007419. PubMed ID: 28639415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship Between Final Visual Acuity and Optical Coherence Tomography Findings in Patients with Diabetic Macular Edema Undergoing Anti-VEGF Therapy.
    Eraslan S; Yıldırım Ö; Dursun Ö; Dinç E; Orekici Temel G
    Turk J Ophthalmol; 2020 Jun; 50(3):163-168. PubMed ID: 32631004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Crossover Design for Comparative Efficacy: A 36-Week Randomized Trial of Bevacizumab and Ranibizumab for Diabetic Macular Edema.
    Wiley HE; Thompson DJ; Bailey C; Chew EY; Cukras CA; Jaffe GJ; Lee RW; Loken EK; Meyerle CB; Wong W; Ferris FL
    Ophthalmology; 2016 Apr; 123(4):841-9. PubMed ID: 26875003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.